Loading quotes...
Forecast
The analysts' average price target is 52,15€ (+287,73%). The median is 53,21€ (+295,61%).
| Buy |
46 |
| Hold |
18 |
| Sell |
0 |
News Go to news feed
Newron Pharmaceuticals: board member Stefan Weber buys shares worth €25,203
Board member Stefan Weber on 12 August 2026 bought Newron Pharmaceuticals shares via Xetra at €12.60 per share, totaling €25,203. The transaction was duly reported and published. » More on de.investing.com
Prisca Anand reports purchase of Newron Pharmaceuticals shares on the SIX
Prisca Anand, in a close relationship with board member Ravi Anand, bought 16,978 shares of Newron Pharmaceuticals on the SIX Swiss Exchange on 10 August 2026 at a price of 11.9733 CHF per share. The transaction was publicly disclosed in accordance with reporting obligations. » More on de.investing.com
Newron: constructive exchange with FDA on continuation of the Evenamide phase-III study
Newron held a Type A meeting with the FDA regarding the suspended recruitment for the Enigma‑TRS 2 phase‑III study of Evenamide. The meeting was constructive; possible measures to address the FDA's concerns were discussed. Newron plans to propose adjustments to address the FDA's issues and hopes for a swift resolution of the open points. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 6.50b | 78,80% |
| Gross profit | 3.64b | 284,73% |
| Net profit | 1.67b | 119,53% |
| EBITDA | 3.48b | 86,37% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 45.53b€ |
Number of shares | 1.10b |
52-week high/low | 45,24€ - 27,01€ |
| Dividends | No |
Beta | 0,42 |
P/E ratio | 11,40 |
PEG ratio | −2,04 |
P/B ratio | 1,08 |
P/S ratio | 2,70 |
Company profile
Newron Pharmaceuticals SpA ist ein biopharmazeutisches Unternehmen. Das Unternehmen hat seinen Hauptsitz in Bresso, Mailand, und beschäftigt derzeit 24 Vollzeitmitarbeiter. Das Unternehmen konzentriert sich auf die Entdeckung und Entwicklung von pharmazeutischen Produkten. Die Firma beschäftigt sich mit der Entdeckung und Entwicklung neuer Therapien für Erkrankungen des Zentralnervensystems (ZNS) und Schmerzen. Das Unternehmen führt Phase-III-Studien mit dem Safinamid-Molekül zur Behandlung von Patienten mit der Parkinsonschen Krankheit durch. Newron Pharmaceuticals SpA entwickelt Ralfinamide, ein Molekül für die Behandlung von neuropathischen Schmerzen. Weitere Projekte wie HF0220 zur Neuroprotektion, NW-3509 zur Behandlung von Schizophrenie sowie Pruvanserin und Sarizotan zur Behandlung von ZNS-Erkrankungen befinden sich in verschiedenen Stadien der präklinischen und klinischen Entwicklung.
| Name | Newron Pharmaceuticals |
| CEO | Clay Gaspar |
| Headquarters | Houston,
tx Italy |
| Website | |
| Industry | Oil, Gas & Consumable Fuels |
| IPO | 07/04/2019 |
| Employees | 2.200 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | NP5.DE |
SIX | NWRN.SW |
London Stock Exchange | 0QOI.L |
Frankfurt | NP5.F |
Düsseldorf | NP5.DU |
London | 0QOI.L |
München | NP5.MU |
NYSE | DVN |
Set | TTT.BK |
Pnk | TINLY |
Discover assets
Shareholders of Newron Pharmaceuticals also invest in the following assets
